SAN DIEGO, July 17, 2012 — Conatus Pharmaceuticals Inc. announced today the appointment of Daniel Ripley as Head of Corporate Development, effective immediately. Mr. Ripley will lead licensing, partnering initiatives, intellectual property analysis and act as the internal coordinator of the emricasan commercialization strategy development. “Dan brings experience in both in-licensing and out-licensing of commercial […]
News
SAN DIEGO, CA and EDMONTON, CANADA, July 19, 2012 — Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor. The objective of the trial is to determine safety, achievement and maintenance of insulin […]
SAN DIEGO, June 11, 2008 — Conatus Pharmaceuticals Inc. announced today that an independent investigator at the Mayo Clinic reported that treatment with CTS-1027 in a preclinical model of liver disease resulted in an attenuation of hepatic fibrosis. These data were presented at the May 2008 Digestive Disease Week (DDW) meeting held in San Diego, […]
SAN DIEGO, March 25, 2008 — Conatus Pharmaceuticals Inc. today announced the appointment of Anthony “Tony” W. Fox as part-time Chief Medical Officer to oversee the recently initiated Phase 2 clinical trial of CTS-1027 in Hepatitis C virus-infected patients as well as assisting in the development of the longer-term clinical development plans. Tony is a […]
SAN DIEGO, March 31, 2011 — Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C virus (HCV) null-responder patient population. Null-responder patients are the most difficult to treat patient population and are clinically defined as […]
SAN DIEGO, April 12, 2011 — Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA. The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February, 2011. Jim Scopa from MPM […]
SAN DIEGO, May23, 2007 — Conatus Pharmaceuticals Inc. today announced the election of Harold Van Wart, Ph.D., to the Companys Board of Directors. Dr. Van Wart currently serves as President and Chief Executive Officer of Metabolex, Inc., a privately-held life science company in Hayward, CA. He joined Metabolex in 2000 as Senior Vice President, Research […]
Former Idun Management team to expand efforts in liver disease and oncology SAN DIEGO, July 30, 2010 — Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc. Financial terms were not disclosed. Conatus Pharmaceuticals is a privately-held drug development company focused on liver disease and oncology. Conatus Pharmaceuticals is […]
SAN DIEGO, October 5, 2009 — Conatus Pharmaceuticals Inc., a privately held, clinical stage company developing a treatment for liver disease associated with Hepatitis C Virus (HCV), announced today that Steven J. Mento, Ph.D., President and Chief Executive Officer, will present at the Montgomery Healthcare Conference being held in Menlo Park, CA, on October 6, […]
SAN DIEGO, August 24, 2006 — Conatus Pharmaceuticals Inc. today announced that it has retained the services of new personnel that complete the key team of technical and business expertise. Joining Conatus is Patricia Contreras, Ph.D., MiRa Huyghe, Sharon Platt and Karen Valentino, Ph.D. “We are pleased to have these critically important personnel join Conatus,” […]